Information Provided By: 
Fly News Breaks for September 28, 2018
ALXN
Sep 28, 2018 | 07:17 EDT
Barclays analyst Geoff Meacham raised his price target for Alexion Pharmaceuticals to $175 saying this week's positive Phase 3 of Soliris data in neuromyelitis optica spectrum disorder "was a positive surprise for many and is the latest in a string of 'wins' for the company." The analyst thinks Alexion remains one of the more compelling names in biotech and he keeps an Overweight rating on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
